HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status
Weitsman G, Barber PR, Nguyen LK, Lawler K, Patel G, Woodman N, Kelleher MT, Pinder SE, Rowley M, Ellis PA, Purushotham AD, Coolen AC, Kholodenko BN, Vojnovic B, Gillett C, Ng T. HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. Oncotarget 2016, 7: 51012-51026. PMID: 27618787, PMCID: PMC5239455, DOI: 10.18632/oncotarget.9963.Peer-Reviewed Original ResearchConceptsGroup of patientsMetastatic relapsePredictive biomarkersHER2 proteinHER2 IHC statusOnly predictive biomarkerInvasive breast cancerNovel prognostic biomarkerOverexpression of HER2Important prognostic markerBreast cancer tissuesHistology-based analysisSignificant clinical utilityHER2-HER3 dimersIHC statusHER2 expressionTissue microarray coresPrognostic markerBreast cancerPrognostic biomarkerHER2-HER3 heterodimersClinical utilityCancer tissuesTumor progressionDriver of proliferation